Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study

Ilaria Cetta(Vita-Salute San Raffaele University), Massimo Filippi(Vita-Salute San Raffaele University), Roberta Messina(Vita-Salute San Raffaele University), Laura Zanandrea(Vita-Salute San Raffaele University), Bruno Colombo(Vita-Salute San Raffaele University)
Neurological Sciences
June 4, 2022
Cited by 27


Related Papers